Ventas Inc. revealed that Sean P. Nolan, former Chief Executive Officer of AveXis Inc., a clinical-stage gene therapy company, has been appointed as an independent member of its Board of Directors.
“Sean is an incredible addition to our diverse, experienced and independent Board of Directors,” said Debra A. Cafaro, Ventas Chairman and CEO. “With three decades of extensive experience in the biopharmaceutical industry and a proven track record of business accomplishment, Sean will contribute unique and complementary insights to enhance our rapidly expanding Research & Innovation business and our enterprise growth.”
“Ventas is a powerful platform with expansive opportunities, and I’m delighted to join the Company’s excellent Board,” said Mr. Nolan. “I look forward to making contributions as the Company gains momentum within the large, dynamic healthcare and biopharmaceutical landscape.”
With Mr. Nolan’s addition, the Ventas Board of Directors totals ten individuals, with nine independent members. Mr. Nolan will initially serve on the Company’s Audit and Compliance Committee.
Sean Nolan, 51, is an accomplished senior executive with more than 28 years of biopharmaceutical experience. He served as Chief Executive Officer and President at AveXis, Inc., a clinical-stage gene therapy company, from 2015 to 2018, successfully growing the company from four employees to a publicly listed company which was acquired by Novartis for $8.7 billion in 2018. Mr. Nolan is Chairman of a gene therapy company, Encoded Therapeutics, Inc., and Executive Chairman of Istari Oncology, Inc. He is also a member of the Board of Directors of Aquinox Pharmaceuticals Inc. (Nasdaq: AQXP), a clinical-stage pharmaceutical company, where he is serves on the Audit Committee and is Chairman of the Nominating and Governance Committee.
Prior to joining AveXis, Mr. Nolan held senior leadership positions at InterMune Inc. (acquired by Roche in 2015), Reata Pharmaceuticals, Inc., Lundbeck, Inc. and Abbott Laboratories.